High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives

Journal of Controlled Release

Volumn 148, Issue 3, 2010, Pages 317-326

  Park, Jin Woo ^a,b   Jeon, Ok Cheol ^c   Kim, Sang Kyoon ^a   Al Hilal, Taslim Ahmed ^a   Jin, Shun Ji ^a   Moon, Hyun Tae ^c   Yang, Victor C ^a,d   Kim, Sang Yoon ^e   Byun, Youngro ^a  

^a Seoul National University   (South Korea)

^b AmorePacific Corporation   (South Korea)

^c Mediplex Corporation   (South Korea)

^d UNIVERSITY OF MICHIGAN   (United States)

^e University of Ulsan College of Medicine   (South Korea)

Author keywords

Antiangiogenesis; Deoxycholic acid; Low molecular weight heparin; Oral delivery; Tumor growth inhibition

Indexed keywords

ANTIANGIOGENESIS; DEOXYCHOLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; ORAL DELIVERY; TUMOR GROWTH INHIBITION;

BIOLOGICAL MATERIALS; CELL CULTURE; DRUG PRODUCTS; ELECTROSTATICS; ENZYME INHIBITION; MOLECULAR WEIGHT; POLYMER BLENDS; TUMORS;

POLYSACCHARIDES;

DEOXYCHOLIC ACID; ETHYLAMINE; LOW MOLECULAR WEIGHT HEPARIN; LOW MOLECULAR WEIGHT HEPARIN DERIVATIVE 1; LOW MOLECULAR WEIGHT HEPARIN DERIVATIVE 1.5; LOW MOLECULAR WEIGHT HEPARIN DERIVATIVE 2; LOW MOLECULAR WEIGHT HEPARIN DERIVATIVE 4; MATRIGEL; N DEOXYCHOLYLETHYLAMINE; NADROPARIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG FORMULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTICOAGULANTS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCHOLIC ACID; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS; SOLUBILITY;

EID: 78649762197     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.09.014     Document Type: Article

References (40)

1. R.J. Hettiarachchi, S.M. Smorenburg, J. Ginsberg, M. Levine, M.H. Prins, and H.R. Buller Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread Thromb. Haemost. 82 1999 947 952
2. G.F. Von Tempelhoff, and L. Heilmann Antithrombotic therapy in gynecologic surgery and gynecologic oncology Hematol. Oncol. Clin. North Am. 14 2000 1151 1169 ix
3. A.Y.Y. Lee, M.N. Levine, R.I. Baker, C. Bowden, A.K. Kakkar, M. Prins, F.R. Rickles, J.A. Julian, S. Haley, M.J. Kovacs, and M. Gent Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J. Med. 349 2003 146 153
4. A.K. Kakkar, M.N. Levine, Z. Kadziola, N.R. Lemoine, V. Low, H.K. Patel, G. Rustin, M. Thomas, M. Quogley, and R.C.N. Williamson Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) J. Clin. Oncol. 22 2004 1944 1948
5. B. Lebeau, C. Chastang, J.M. Brechot, F. Capron, B. Dautzenberg, C. Delaisements, M. Mornet, J. Brun, J.P. Hurdebourcq, and E. Lemarie Subcutaneous heparin treatment increases survival in small cell lung cancer Cancer 74 1994 38 45 (Pubitemid 24187607)
6. M. Presta, D. Leali, H. Stabile, R. Ronca, M. Camozzi, L. Coco, E. Moroni, S. Liekens, and M. Rusnati Heparin derivatives as angiogenesis inhibitors Curr. Pharm. Des. 9 2003 553 566
7. H. Takahashi, S. Ebihara, T. Okazaki, M. Asada, H. Sasaki, and M. Yamaya A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumor angiogenesis and heparanase activity Br. J. Pharmacol. 146 2005 333 343
8. J. Hasan, S.D. Shnyder, A.R. Clamp, A.T. McGown, R. Bicknell, M. Presta, M. Bibby, J. Double, S. Craig, D. Leeming, K. Stevenson, J.T. Gallagher, and G.C. Jayson Heparin octassacharide inhibit angiogenesis in vivo Clin. Cancer Res. 11 2005 8172 8179
9. K. Norrby Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically Haemostasis 23 1993 141 149
10. C. Pisano, C. Aulicino, L. Vesci, B. Casu, A. Naggi, G. Torri, D. Ribatti, M. Belleri, M. Rusnati, and M. Presta Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenetic VEGF antagonist Glycobiology 15 2005 1C 6C
11. M. Jaya, J. Schlessinger, and C.A. Dionne Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction Biochim. Biophys. Acta 1135 1992 185 199
12. E. Ruoslahti, and Y. Yamaguchi Proteoglycans as modulators of growth factor activities Cell 64 1991 867 869
13. J.L. Andres, D. DeFalcis, M. Noda, and J. Massague Binding of two growth factor families to separate domains of the proteoglycan betaglycan J. Biol. Chem. 267 1992 5927 5930
14. S. Colin, J.C. Jeanny, F. Mascarelli, R. Vienet, S. Al-Mahmood, Y. Courtois, and J. Labarre In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor Mol. Pharmacol. 55 1999 74 82
15. O. Saksela, D. Moscatelli, A. Sommer, and D.B. Rifkin Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation J. Cell Biol. 107 1988 743 751
16. M. Rusnati, and M. Presta Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans, biological implications in neovascularization Int. J. Clin. Lab. Res. 26 1996 15 23
17. I. Vlodavsky, R. Ishai-Michaeli, M. Mohsen, R. Bar-Shavit, R. Catane, H.P. Ekre, and C.M. Svahn Modulation of neovascularization and metastasis by species of heparin Adv. Exp. Med. Biol. 313 1992 317 327
18. T.M.H. Niers, C.P.W. Klerk, M. DiNisio, C.J.F. Van Noorden, H.R. Buller, P.H. Reitsma, and D.J. Richel Mechanism of heparin induced anti-cancer activity in experimental cancer models Crit. Rev. Oncol. Hematol. 61 2007 195 207
19. K. Ono, M. Ishihara, K. Ishikawa, Y. Ozeki, H. Deguchi, and M. Sato Periodate-treated, non-anticoagulant heparin carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung Br. J. Cancer 86 2002 1803 1812
20. P.E. Thorpe, E.J. Derbyshire, S.P. Andrade, N. Press, P.P. Knowles, S. King, G.J. Watson, Y.C. Yang, and M. Rao-Bette Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice Cancer Res. 53 1993 3000 3007
21. L. Lundin, H. Larsson, J. Kreuger, S. Kanda, U. Lindahl, M. Salmivirta, and L. Claesson-Welsh Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis J. Biol. Chem. 275 2000 24653 24660
22. C.Y. Pumphrey, A.M. Theus, S. Li, R.S. Parrish, and R.D. Sanderson Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis Cancer Res. 62 2002 3722 3728
23. K. Park, Y.S. Kim, G.Y. Lee, J.O. Nam, S.K. Lee, R.W. Park, S.Y. Kim, I.S. Kim, and Y. Byun Antiangiogenic effect of bile acid acylated heparin derivative Pharm. Res. 24 2007 176 185
24. D.Y. Lee, K. Park, S.K. Kim, R. Park, I.C. Kwon, S.Y. Kim, and Y. Byun Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis Clin. Cancer Res. 14 2008 2841 2849
25. Y.K. Lee, J.H. Nam, H.C. Shin, and Y. Byun Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent Circulation 104 2001 3116 3120
26. A. Fini, G. Fazio, A. Roda, A.M. Bellini, E. Mencini, and M. Guarneri Basic cholane derivatives. XI: comparison between acid and basic derivatives J. Pharm. Sci. 81 1992 726 730
27. D.S. Grant, K. Tashiro, B. Segui-Real, Y. Yamada, G.R. Martin, and H.K. Kleinman Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro Cell 58 1989 933 943
28. L.A. Fransson, and I. Carlstedt Alkaline and smith degradation of oxidized dermatan sulphate-chondroitin sulphate copolymers Carbohydr. Res. 36 1974 349 358
29. Y. Yoshitomi, H. Nakanishi, Y. Kusano, S. Munesue, K. Oguri, M. Tatematsu, I. Yamashina, and M. Okayama Inhibition of experimental lung metastasis of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity Cancer Lett. 207 2004 165 174
30. F. Lapierre, K. Holme, L. Lam, R.J. Tressler, N. Storm, and J. Wee Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties Glycobiology 6 1996 355 366
31. A.L. Stone Optical rotary dispersion of mucopolysaccharides III. Ultraviolet circular dichroism and conformation al specificity in amide groups Biopolymers 10 1971 739 751
32. M.C.M. Chung, and N.F. Ellerton Viscosity at low shear and circular dichroism studies of heparin Biopolymers 15 1976 1409 1423
33. A.A. Powell, J.M. Larue, A.K. Batta, and J.D. Martinez Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells Biochem. J. 356 2001 481 486
34. 165 to its receptors Biochem. Biophys. Res. Commun. 203 1994 1339 1347
35. A. Lepri, U. Benelli, N. Bernardini, F. Bianchi, M. Lupetti, R. Danesi, M. Del Tacca, and M. Nardi Effect of low molecular weight heparan sulfate on angiogenesis in rat cornea after chemical cauterization J. Ocul. Pharmacol. 10 1994 273 280
36. S. Guimond, M. Maccarana, B.B. Olwin, U. Lindahl, and A.C. Rapraeger Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4 J. Biol. Chem. 268 1993 23906 223914
37. P. Bellosta, A. Iwahori, A.N. Plotnikov, A.V. Eliseenkova, C. Basilico, and M. Mohammadi Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis Mol. Cell. Biol. 21 2001 5946 5957
38. E. Lee, Y. Kim, S.M. Bae, S.K. Kim, S. Jin, S.W. Chung, M. Lee, H.T. Moon, O.C. Jeon, R.W. Park, I.S. Kim, Y. Byun, and S.Y. Kim Polyprolin-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor Int. J. Cancer 124 2009 2755 2765
39. S.K. Kim, D.Y. Lee, E.H. Lee, Y.K. Lee, C.Y. Kim, H.T. Moon, and Y. Byun Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anticoagulant J. Control. Release 120 2007 4 10
40. J.W. Park, O.C. Jeon, S.K. Kim, T.A. Al-Hilal, H.T. Moon, C.Y. Kim, and Y. Byun Anticoagulant efficacy of solid oral formulations containing a new heparin derivative Mol. Pharm. 7 2010 836 843